Trademark Overview
On Thursday, May 16, 2024, a trademark application was filed for CONCORDIA RX with the United States Patent and Trademark Office. The USPTO has given the CONCORDIA RX trademark a serial number of 98553736. The federal status of this trademark filing is NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER as of Thursday, May 16, 2024. This trademark is owned by Concordia Pharmaceuticals Inc., S.à.r.L. The CONCORDIA RX trademark is filed in the Pharmaceutical Products category with the following description:
a full line of pharmaceuticals for the treatment of depression, hypertension, malaria, metastatic prostate cancer, benign prostatic hyperplasia, partial seizures in adults with epilepsy, attention deficit hyperactivity disorder (ADHD), heart failure in adults, heart failure in pediatric patients, atrial fibrillation in adults, edema associated with congestive heart failure, edema associated with cirrhosis of the liver, edema associated with nephrotic syndrome, steroid-induced edema, idiopathic edema, edema due to secondary hyperaldosteronism, irritable bowel syndrome (irritable colon, spastic colon, mucous colitis), acute enterocolitis, and duodenal ulcer; anti-inflammatory medicines and immunosuppressive agents (corticosteroids)
